{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'taken with food (eg, a snack) and', 'stomach.', 'should not be taken on an empty', 'Dosing will be based on body', 'stomach.', 'weight and CYP2D6 impairment status', 'Dosing will be based on body', 'at the baseline visit, as shown in Table', 'weight and CYP2D6 impairment status', '2.', 'at the baseline visit and strong', 'The starting dose is 6 mg in all', 'CYP2D6 inhibitor use, as shown in', 'patients. Daily doses will be', 'Table 2 and Table 3.', 'administered twice daily,', 'The starting dose is 6 mg in all', 'approximately 8 to 10 hours apart', 'patients. This dose will be administered', 'during the day. A minimum of 6 hours', 'in the evening on days 1 and 2,', 'should elapse between doses. If a', 'followed by AM administration for the', 'patient misses a dose and it is within', 'remainder of week 1 (if body weight is', '6 hours of their next dose, the missed', '<40 kg). Subsequent Daily doses of', 'dose should be skipped.', '12 mg and higher will be administered', 'After week 1, dose increases may', 'twice daily in 2 divided doses,', 'not occur more frequently than every', 'approximately 8 to 10 hours apart', '5 days.', 'during the day. A minimum of 6 hours', 'Dose reductions, if required,', 'should elapse between doses. If a', 'should be in increments of 6 mg. If', 'patient misses a dose and it is within', 'more than 1 dose reduction is required', '6 hours of their next dose, the missed', 'for an adverse event, the medical', 'dose should be skipped. If patients', 'monitor should be notified.', 'experience insomnia while taking the', 'initial 6 mg dose in the evening, they', 'During the titration period, the', 'may switch to taking it as a morning', 'dose of the IMP will be adjusted', 'dose on day 2.', 'weekly according to Table 2 to identify', 'a dose level that optimally reduces tics', 'After week 1, dose increases may', 'and is well tolerated. Investigators will', 'not occur more frequently than every', 'be blinded to CYP status, with a dose', '5 days.', 'cap for poor metabolizers prespecified', 'Dose reductions, if required, should', 'by the IRT.', 'be in increments of 6 mg. If more than', 'IMP will be packaged in blister packs', '1 dose reduction is required for an', 'and provided for patients to take at', 'adverse event, the medical monitor', 'home (see Section 3.8).', 'should be notified.', 'During the titration period, the dose', 'of the IMP should will be adjusted', 'weekly according to Table 2 to identify', 'a dose level that optimally reduces tics', '(as determined by the investigator, in', 'consultation with the patient \u20ac', 'earegiver/adult) and is well tolerated.', 'Investigators will be blinded to CYP', 'status, with a dose cap for poor', 'metabolizers prespecified by the IRT.', 'IMP will be packaged in bottles blister', 'packs and provided for patients to take', '147']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'at home (see Section 3.8).', 'Table 2 was updated', 'Table 2 was updated to include CYP', 'Updates wer made to', 'Impairment status. Column headers', 'account for CYP2D6', 'remained divided by weight, but also to', 'genotyping status', 'include \"not impaired\" versus', 'determined at', '\"impaired\" daily doses by weight', 'baseline, and to', 'categories. Additional editorial changes', 'specify daily dosing', 'were made to the table and table', 'from baseline', 'footnotes to more clearly specify daily', 'through week 6', 'dosing expectations by weight category', 'based on both weight', 'and by CYP impairment status, and to', 'category and CYP', 'enhance study visit clarity.', 'impairment.', 'Table 3 from version 01 was removed.', 'Table 3 from the previous version', 'Table 3 was removed', 'protocol amendment 01 was removed,', 'to remove duplicate', 'as Table 2 was updated to include the', 'protocol detail.', 'additional information provided by this', 'table.', '5.3 Prior and Concomitant Medications', 'Medications that are allowed, provided', 'Medications that are allowed, provided', 'Updates were made', 'that conditions outlined in the table are', 'that conditions outlined in the table are', 'to clarify that the', 'met, are shown in Appendix A, Table \u20ac', 'met, are shown in Appendix A,', 'addition of strong', 'Table 5.', 'Table 5.', 'CYP inhibitors are', 'The medical monitor must be contacted', 'The medical monitor must be contacted', 'prohibited once a', 'if a patient is receiving (or has to begin', 'if a patient is receiving (or has to begin', 'patient is enrolled. In', 'or stop receiving during the study) a', 'or stop receiving during the study) a', 'addition, prohibited', 'medication that is associated with QTc', 'medication that is associated with QTc', 'medications', 'prolongation or that is a known strong', 'prolongation or that is a known strong', 'associated with QTc', 'CYP inhibitor.', 'CYP inhibitor.', 'prolongation have', 'been inserted into the', 'Addition of a strong CYP inhibitor is', 'Addition of a strong CYP inhibitor is', 'prohibited.', 'prohibited.', 'protocol appendices', 'and are referenced', 'Prohibited medications that are', 'Prohibited medications that are', 'here.', 'associated with QTc prolongation are', 'associated with QTc prolongation are', 'listed in Appendix A, Table 6, while', 'listed in Appendix A, Table 6, while', 'prohibited antipsychotic drugs are', 'prohibited antipsychotic drugs are', 'listed in Appendix A, Table 7.', 'listed in Appendix A, Table 7.', '6.2.2 Tourette Syndrome-Patient Global Impression of Impact', 'The TS-PGII is administered at', 'The TS-PGII is administered at', 'The TS-PGII was', 'baseline and weeks 2, 4, 6, 9, 12, and', 'baseline and weeks 2, 4, 6, 9, 12, and', 'included as a key', '13. Input from the caregiver/adult is', '13. Input from the caregiver/adult is', 'secondary efficacy', 'permitted.', 'permitted.', 'endpoint, so a brief', '148']\n\n###\n\n", "completion": "END"}